Dr. Seth Lederman is a physician, scientist, and entrepreneur with over two decades of experience in biopharmaceutical research and development. As the co-founder, CEO, and Chairman of Tonix Pharmaceuticals, Dr. Lederman has been instrumental in advancing the company's mission to develop innovative therapies addressing unmet needs in CNS diseases, immunology, and infectious diseases. A board-certified internist and rheumatologist, Dr. Lederman began his career as an Associate Professor at Columbia University, where he co-discovered the CD40-Ligand, a breakthrough finding that contributed to the development of several FDA-approved treatments. He is an inventor on numerous patents and has authored more than 50 scientific publications. Under his leadership, Tonix has focused on a diverse pipeline, including treatments for post-traumatic stress disorder (PTSD), fibromyalgia, and infectious diseases like smallpox and COVID-19. Dr. Lederman's strategic vision has led to significant advancements in drug development and partnerships with academic and government institutions. Dr. Lederman earned his MD from Columbia University College of Physicians and Surgeons. He is widely recognized for his expertise in translational medicine and his contributions to advancing new therapeutics.